Featured
-
-
Research Highlights |
Feedback loop in lupus
-
News |
First lupus drug in half a century approved
A therapeutic antibody is the first success in a wave of experimental therapies aimed at tackling the autoimmune disease.
- Heidi Ledford
-
News |
Strange lesions after stem-cell therapy
Unproven treatment results in mysterious masses.
- David Cyranoski
-
Letter |
TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus
Glucocorticoids are widely used to treat patients with autoimmune diseases such as systemic lupus erythematosus (SLE), but many treatment regimens cannot maintain disease control in SLE patients. Here it is shown that the stimulation of plasmacytoid dendritic cells through toll-like receptors TLR7 and TLR9 can account for the reduced activity of glucocorticoids to inhibit the type I interferon pathway in SLE patients. Thus inhibitors of TLR7 and TLR9 signalling might prove to be effective corticosteroid-sparing drugs.
- Cristiana Guiducci
- , Mei Gong
- & Franck J. Barrat